UBS Group
CDIO icon

UBS Group’s Cardio Diagnostics CDIO Stock Holding History

UBS Group’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3K Buy
9,919
+8,967
+942% +$23.5K ﹤0.01% 7962
2025
Q4 		$2.58K Buy
+952
New +$3.46K ﹤0.01% 9280
2025
Q3 		– Sell
-697
Closed -$2.51K – 10374
2025
Q2 		$2.51K Sell
697
-4,874
-87% -$36.4K ﹤0.01% 9452
2025
Q1 		$55.2K Buy
5,571
+3,351
+151% +$52.2K ﹤0.01% 7509
2024
Q4 		$61.1K Buy
+2,220
New +$30.8K ﹤0.01% 7177
2024
Q3 		– Sell
-3,030
Closed -$50K – 9538
2024
Q2 		$50K Buy
3,030
+2,613
+627% +$61.5K ﹤0.01% 6689
2024
Q1 		$17.8K Buy
+417
New +$23.8K ﹤0.01% 6975
2023
Q4 		– Sell
-2
Closed -$21 – 9349
2023
Q3 		$21 Buy
+2
New +$48 ﹤0.01% 9113
2023
Q2 		– Sell
-89
Closed -$10.5K – 8979
2023
Q1 		$10.5K Buy
89
+43
+93% +$3.39K ﹤0.01% 7575
2022
Q4 		$1.47K Buy
46
+30
+188% +$3.24K ﹤0.01% 9859
2022
Q3 		$5K Hold
16
– – ﹤0.01% 9171
2022
Q2 		$5K Buy
16
+6
+60% +$1.79K ﹤0.01% 8849
2022
Q1 		$3K Buy
+10
New +$2.96K ﹤0.01% 9428

Other funds holding CDIO

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

UBS Group's CDIO Position: Q1 2026 in Review

UBS Group increased its Cardio Diagnostics (CDIO) stake by 942% in Q1 2026, buying an estimated $23.5K and bringing the position to 9,919 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7962.

UBS Group first reported a position in CDIO in Q1 2022 and has held it in 13 quarters since. The position peaked at $61.1K in Q4 2024. 16 funds tracked by Wall St. Rank hold CDIO as of Q1 2026.

  • UBS Group held 9,919 shares of Cardio Diagnostics worth $19.3K as of Q1 2026.
  • UBS Group bought 8,967 Cardio Diagnostics shares in Q1 2026, an estimated $23.5K.
  • Cardio Diagnostics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7962 holding.
  • UBS Group first reported a position in Cardio Diagnostics in Q1 2022 and has held it in 13 quarters since.
  • UBS Group's Cardio Diagnostics position peaked at $61.1K in Q4 2024.
  • 16 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.